["{\n\"step_by_step_thinking\": \"The provided documents describe various studies on bispecific antibodies (bsAbs) targeting T cells towards B cell lymphomas. Chimeric antibodies with specificity for the human alpha/beta T cell receptor are also discussed. However, there is no specific mention of chimeric antigen receptor (CAR)-T cell therapies. Therefore, it can be inferred that CAR-T cell therapies have not been directly approved for the treatment of B cell malignancies based on these studies.\",\n\"answer_choice\": \"B: no\""]